Efficacy and effectiveness of incretin-based therapies in body weight reduction Randomized controlled trials (RCT) Liraglutide, titrated up to 3.0 mg administered subcutaneously once daily (OD), was the first incretin-based AOM to be developed and launched on the market
The medication has been shown to significantly reduce HbA1c levels (a measure of long-term blood sugar control) and promote weight loss
You should contact your GP or diabetes care team if you experience any of the following : Sudden or rapidly progressive swelling of the face, lips, tongue, or throat, which could indicate an allergic reaction (angioedema) Swelling accompanied by shortness of breath , particularly when lying flat, which may suggest heart failure Unilateral leg swelling (affecting only one leg), especially if associated with pain, warmth, or redness, as this could indicate deep vein thrombosis requiring same-day assessment Swelling with significant weight gain (more than 23 kg in a few days) without dietary explanation Peripheral oedema with reduced urine output or changes in urine colour, which might indicate kidney problems Abdominal swelling with pain or discomfort , particularly if accompanied by nausea or vomiting Seek immediate medical attention (call 999 or attend A&E) if you experience : Severe difficulty breathing or chest pain alongside swelling Facial swelling with difficulty swallowing or breathing Signs of severe allergic reaction (anaphylaxis) Sudden, severe abdominal pain that could indicate pancreatitis if pancreatitis is suspected, stop taking Ozempic immediately For non-urgent concerns, schedule an appointment with your GP or diabetes specialist nurse to discuss your symptoms
For a broader perspective on affordable compounded GLP-1 options , comparing multiple providers and pharmacies can help you find the best value for your situation
The journey from initial adjustment through potential plateaus to maintenance dosing involves evolving timing needs at each stage
